-
May 26, 2020 Canada’s largest pharmaceutical manufacturer donates thousands of bottles of hand sanitizer to hospitals across Quebec
-
May 25, 2020 Toronto Company Launches Hiring Blitz During COVID-19
-
Apr 21, 2020 Canada’s Apotex Donates Two Million Dosages of Hydroxychloroquine to the Public Health Agency of Canada
-
Apr 17, 2020 Canada's Apotex Donates Critical N95 Masks to Support Frontline Healthcare Workers
-
Apr 13, 2020 Canada's Largest Pharmaceutical Company Produces Hand Sanitizer to Support the Fight Against COVID-19
-
Mar 20, 2020 Apotex Donates Hydroxychloroquine for a Clinical Study to Prevent Infection From Covid-19 With Front Line Health Care Workers
-
Feb 4, 2020 Voluntary Recall of APO-METFORMIN ER (Metformin Hydrochloride Extended-Release Tablets) 500mg Tablets.
-
Dec 5, 2019 Apotex Releases New Supply of Tamoxifen into Canadian Market
-
Jun 1, 2018 Apotex Builds Momentum in Canada's Biosimilar Market After World's First Approval
-
Sep 1, 2017 VOLUNTARY NATIONWIDE RECALL: One lot of APO-NITROGLYCERIN (Nitroglycerin Sublingual Spray) Apotex standard, 0.4MG/Metered dose due to possibility of non-spraying pump
-
Feb 9, 2017 VOLUNTARY NATIONWIDE RECALL: One lot of ALYSENA™ 28 (Levonorgestrel and Ethinyl Estradiol tablets, USP 100 mcg/20 mcg) Due to Possibility of Broken/Chipped Tablets
-
Mar 31, 2016 Launch of Key Biosimilar Medicine To Help Save Healthcare Budgets
-
Mar 24, 2016 Apotex Launches First Generic Version of Merck's Nasonex®
Media inquries
Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.
Latest news
-
Oct 23, 2025
Apotex Receives Health Canada Approval for LOQTORZI® - The First and Only Immuno-Therapy for Recurrent Unresectable or Metastatic Nasopharyngeal Cancer
Toronto, ON - October 23, 2025 - Apotex Inc. ("Apotex" or the "Company"), the largest Canadian-based pharmaceutical company, today announced that Health Canada has granted a Notice of Compliance (NOC) for LOQTORZI® (toripalimab) for the treatment of nasopharyngeal carcinoma (NPC), an ultra-rare and aggressive cancer.
-
Oct 8, 2025
Apotex supports launch of home-based cancer care with $1.5M donation
Apotex is helping bring oncology care directly into patients' homes through a $1.5 million donation to Sunnybrook Foundation. The contribution supports the launch of Cancer Care at Home, a new initiative under the Odette Cancer Program that delivers timely cancer care where patients live.
-
Oct 7, 2025
Apotex Strengthens Commitment to Women's Health with Exclusive Canadian Rights to "Linzagolix" for Uterine Fibroid Treatment
Searchlight Pharma Inc.(“Searchlight”), Apotex Inc’s (“Apotex”) Branded Medicines Division today announced it has entered into a strategic licensing agreement securing exclusive Canadian rights to linzagolix, a once-daily oral treatment developed by Kissei Pharmaceutical Co., Ltd. Linzagolix belongs to a class of medicines called GnRH antagonists.